



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

July 6, 2022

Renée Aguiar-Lucander  
Chief Executive Officer  
Calliditas Therapeutics AB  
Kungsbron 1, D5  
SE-111 22  
Stockholm, Sweden

**Re: Calliditas Therapeutics AB**  
**Registration Statement on Form F-3**  
**Filed June 28, 2022**  
**File No. 333-265881**

Dear Ms. Aguiar-Lucander:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Ada D. Sarmento at 202-551-3798 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Joshua A. Kaufman, Esq.